LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (“Olema” or “the Company”) (NASDAQ: OLMA) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Olema is the subject of an Investor’s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema’s competing medication. According to analyst Matthew Biegler, the Roche results “comes with a dent to the thesis that oral SERDs can win in front-line breast cancer.” Based on this news, shares of Olema fell by more than 19.6% in morning trading on the same day.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contacts
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
